Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
Emergent BioSolutions secured a contract modification valued at approximately $24 million from BARDA to supply its CYFENDUS vaccine for anthrax preparedness efforts. The award builds on the company's existing relationship with the U.S. government, following a prior $21.5 million delivery order for BioThrax earlier this year.
Key figures
- Deal Value Usd
- 24000000
- Prior delivery order value
- 21500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.